Oric Pharmaceuticals, Inc. (ORIC) · Oct 23, 2026 · Other events
Phase 3 advancement — 84% confirmed systemic ORR; 67% BICR CNS ORR; Redwood-1 planned for 1H 2027
ORIC’s enozertinib clinical update shows deep systemic and brain responses in EGFR atypical lung cancer, supporting a global Phase 3 launch in 2027.
ORIC is a late-stage oncology company advancing two lead programs: rinzimetostat is already in Phase 3, while enozertinib is being developed as a CNS-active targeted therapy for EGFR atypical and exon 20 non-small-cell lung cancer. Before this filing, the company had already signaled an enozertinib clinical update in the second half of 2026 and a possible registrational path, with roughly $388 million of cash and investments expected to fund operations into the second half of 2028.
The clinical signal is materially stronger than a routine update. In first-line EGFR atypical NSCLC, enozertinib produced an 84% confirmed systemic response rate in 25 response-evaluable patients, while blinded central review confirmed an 80% rate. Its central-nervous-system activity was also substantial: 70% confirmed intracranial response by investigator assessment and 67% by the more stringent BICR RANO-BM assessment, including six complete responses. The result is notable because 65% of the 26-patient safety population had baseline brain metastases, including 46% with previously untreated brain metastases. 〔0〕
| Measure | Enozertinib result | Comparison / context |
|---|---|---|
| Confirmed systemic ORR | 84% investigator; 80% BICR | Competitor programs shown at roughly 50%–68% (Clinical data benchmarks) |
| Confirmed intracranial ORR | 70% investigator; 67% BICR RANO-BM | Competitor programs shown at roughly 29%–40% (Clinical data benchmarks) |
| Six-month landmark PFS | 88% | Comparator benchmarks shown at roughly 65%–75% (Clinical data benchmarks) |
| Treatment discontinuations due to adverse events | 0% | No treatment-related discontinuations (Safety and tolerability profile) |
| Baseline CNS metastases | 65% of N=26 | Nearly half had untreated brain metastases (Demographics and baseline characteristics) |
The filing converts promising Phase 1b data into a credible registrational plan. ORIC says its End-of-Phase 1 FDA interactions aligned on the recommended Phase 3 dose, endpoints, statistical methodology, patient population and control arm, supporting a randomized Redwood-1 study against osimertinib or afatinib. This is the key business change: the program moves from “potentially registrational” to an FDA-aligned Phase 3 design with a stated launch window.
The main qualification is maturity, not an obvious efficacy problem. Follow-up was only 10.5 months, median progression-free survival and duration of response were not yet mature, and the dataset is small and single-arm. The filing reports that the median time on treatment had not been reached and that most patients remained on therapy. 〔1〕 Safety also looks manageable in this early dataset: adverse events were mainly Grade 1 or 2, no Grade 4 or 5 treatment-related adverse events occurred, and there were no treatment-related discontinuations. 〔2〕
Bottom line: This is a meaningful upgrade to enozertinib’s development story: unusually strong early systemic and CNS activity now supports a defined Phase 3 path. The evidence is still immature and based on a small cohort, but the filing advances the program rather than merely confirming an already-scheduled milestone.
Redwood-1 Phase 3 initiation, 1H 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!